Consistent with reports on the prevalence and clinical implications of PIK3CA aberrations across cancer types [33] and the emerging role of PTEN alterations in NSCLC biology [34], these variants help refine prognostic expectations and may signal mechanisms of resistance to other therapies. This evidence concerns the gene PTEN and cancer.